Amneal Pharmaceuticals, Inc. AMRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Affordable Medicines | $1.75B+0.5% | $1.75B-0.2% | $1.75B+1.9% | $1.71B+0.4% | $1.71B+1.4% | |
| AvKARE | $738.33M-0.9% | $744.73M+5.7% | $704.37M+5.9% | $665.33M-1.1% | $672.7M+1.5% | |
| Net revenue by Product | ||||||
| Auto-Injector | $226.55M-2.7% | $232.8M+0.5% | $231.6M+3.7% | $223.35M+3.9% | $215.04M+2.6% | |
| Biosimilar | $93.99M-6.2% | $100.23M-8.3% | $109.35M-11.1% | $123.02M-3.3% | $127.27M+1.5% | |
| Central nervous system | $349.19M+4.7% | $333.42M+9.2% | $305.26M+1.4% | $301.03M+6.9% | $281.51M+0.5% | |
| Distribution | $392.71M-3.9% | $408.46M+0.3% | $407.3M-1.3% | $412.69M-3.8% | $429.16M-1.1% | |
| Government label | $279.91M+3.6% | $270.11M+17.3% | $230.17M+24.9% | $184.35M+5.3% | $175.15M+9.5% | |
| Hormonal / allergy | $156.66M+1.1% | $154.93M+7.4% | $144.3M+3.9% | $138.89M+2.7% | $135.25M+3.7% | |
| Injectable | $176.39M+9.4% | $161.24M-6.1% | $171.76M+7.0% | $160.56M-2.7% | $165M-0.3% | |
| Institutional | $34.19M-3.4% | $35.38M-6.2% | $37.72M-8.6% | $41.27M-3.8% | $42.9M+0.4% | |
| International | $16.21M+33.7% | $12.13M+13.1% | $10.72M+19.9% | $8.94M+5.6% | $8.47M-5.4% | |
| Oral liquid | $61.37M-15.7% | $72.82M-11.9% | $82.7M-6.9% | $88.82M-6.5% | $95.04M-8.1% | |
| Oral solid | $718.53M-1.1% | $726.38M+0.8% | $720.63M+2.7% | $701.38M+0.3% | $699.08M+1.4% | |
| Other dosage forms | $242.61M-3.9% | $252.42M+3.8% | $243.24M+3.8% | $234.23M+8.8% | $215.34M+6.5% | |
| Other therapeutic classes | $47.13M+18.8% | $39.66M+22.6% | $32.36M+6.6% | $30.35M+1.1% | $30.01M+4.8% | |
| Subtotal dosage forms | $1.74B+0.3% | $1.73B-0.2% | $1.74B+1.9% | $1.71B+0.3% | $1.7B+1.4% | |
| Subtotal therapeutic classes | $552.98M+4.7% | $528.01M+9.6% | $481.92M+2.5% | $470.27M+5.3% | $446.76M+1.7% | |
| Transdermal | $218.41M+16.5% | $187.51M+5.2% | $178.18M+2.1% | $174.47M-4.9% | $183.46M+1.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.